Holen Sie sich die Stockscreener-App
1.28
3.23%
0.04
Handel nachbörslich:
1.27
-0.01
-0.78%
Schlusskurs vom Vortag:
$1.24
Offen:
$1.22
24-Stunden-Volumen:
10,519
Relative Volume:
0.03
Marktkapitalisierung:
$34.46M
Einnahmen:
$9.06M
Nettoeinkommen (Verlust:
$-50.39M
KGV:
-0.6667
EPS:
-1.92
Netto-Cashflow:
$5.89M
1W Leistung:
-2.29%
1M Leistung:
+0.79%
6M Leistung:
-32.63%
1J Leistung:
-58.71%
1-Tages-Spanne:
$1.22
$1.28
1-Wochen-Bereich:
$1.20
$1.33
52-Wochen-Spanne:
$0.8502
$3.20
Lava Therapeutics Nv Stock (LVTX) Company Profile
Firmenname
Lava Therapeutics Nv
Sektor
Branche
Telefon
31 6 3000 3035
Adresse
YALELAAN 62, UTRECHT
Vergleichen Sie LVTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LVTX
Lava Therapeutics Nv
|
1.28 | 34.46M | 9.06M | -50.39M | 5.89M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Lava Therapeutics Nv Stock (LVTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-12 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-12-11 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-19 | Eingeleitet | JP Morgan | Overweight |
| 2021-04-19 | Eingeleitet | Jefferies | Buy |
| 2021-04-19 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Lava Therapeutics Nv Aktie (LVTX) Neueste Nachrichten
LAVA Therapeutics Strengthens Balance Sheet with $5.1 Million Repayment Waiver from Netherlands Enterprise Agency - Nasdaq
Lava Therapeutics Granted Full Waiver For RVO Payment Obligation - marketscreener.com
LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation - GlobeNewswire
LAVA Therapeutics Strengthens Balance Sheet: Secures Complete Waiver of $5.1M Debt - Stock Titan
Investors Aren't Buying LAVA Therapeutics N.V.'s (NASDAQ:LVTX) Revenues - simplywall.st
Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads after asset cut - Investing.com India
LAVA Therapeutics (NASDAQ:LVTX) Receives Neutral Rating from HC Wainwright - Defense World
Leerink cuts Lava Therapeutics stock target to $1 By Investing.com - Investing.com Canada
Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads after asset cut By Investing.com - Investing.com South Africa
Leerink cuts Lava Therapeutics stock target to $1 - Investing.com
JMP maintains LAVA Therapeutics stock Market Perform rating By Investing.com - Investing.com Australia
JMP maintains LAVA Therapeutics stock Market Perform rating - Investing.com
Lava Therapeutics Reports 2024 Financial Results - TipRanks
LAVA Therapeutics NV earnings beat by $0.16, revenue topped estimates - Investing.com Australia
LAVA Therapeutics N.V. (LVTX) reports earnings - Quartz
LAVA Therapeutics NV SEC 10-K Report - TradingView
LAVA Therapeutics NV reports results for the quarter ended December 31Earnings Summary - TradingView
LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - GlobeNewswire
LAVA Therapeutics Q4 Basic EPS USD -0.14 - MarketScreener
LAVA Therapeutics Slashes Workforce 30% While Securing $12M in Big Pharma Milestone Payments - Stock Titan
Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads amid pipeline shifts By Investing.com - Investing.com South Africa
Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads amid pipeline shifts - Investing.com
Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang - Benzinga
This Constellation Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Benzinga
LAVA Therapeutics Reviews Strategic Alternatives, Announces 30% Staff Cut - Nasdaq
LAVA Therapeutics Announces Restructuring Plan for 2025 - TipRanks
LAVA Announces Evaluation of Strategic Options - GlobeNewswire
Can LAVA Therapeutics Find a Buyer? Company Cuts 30% of Staff While Exploring Strategic Options - StockTitan
LVTX stock touches 52-week low at $0.88 amid market challenges - Investing.com Australia
LVTX stock touches 52-week low at $0.88 amid market challenges By Investing.com - Investing.com South Africa
LAVA Therapeutics (NASDAQ:LVTX) Stock Price Down 4.6% – Here’s What Happened - Defense World
RNA Editing Market Top Companies StudyQIAGEN N.V., UniquQuire - openPR
LAVA Therapeutics begins trial for cancer treatment - Investing.com India
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers - GlobeNewswire
LAVA Therapeutics Initiates Phase 1 Trial for Novel Leukemia Treatment LAVA-1266 - StockTitan
LAVA Therapeutics NV (LVTX)’S -5.56% Retreat Makes It Worth Considering Again - Stocks Register
LAVA Therapeutics NV Files 8-K with SEC, Transitioning to U.S. Domestic Issuer Status - Defense World
LVTX stock touches 52-week low at $0.95 amid market challenges - Investing.com
H.C. Wainwright maintains Buy on Lava Therapeutics shares despite pipeline reprioritization By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Lava Therapeutics shares despite pipeline reprioritization - Investing.com
LAVA Therapeutics stock hits 52-week low at $0.98 - Investing.com
Finanzdaten der Lava Therapeutics Nv-Aktie (LVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.47%
2.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):